Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer

BACKGROUND: Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost‐effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer. METHODS: Pre‐ and in‐treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Min, Huang, Chao, Zhou, Huan, Liu, Dan, Chen, Runze, Li, Xiuhua, Cheng, Ye, Gao, Bing, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720633/
https://www.ncbi.nlm.nih.gov/pubmed/34791810
http://dx.doi.org/10.1111/1759-7714.14230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720633/
https://www.ncbi.nlm.nih.gov/pubmed/34791810
http://dx.doi.org/10.1111/1759-7714.14230

Ejemplares similares